Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093663 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
NCT02093663 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 107 participants.
The verdict
NCT02093663, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
Study Summary
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
Interventions
- DRUG MMX Mesalamine/Mesalazine (Low Dose)
- DRUG MMX Mesalamine/Mesalazine (High Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2014-12-12 |
| Est. Completion | 2018-11-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093663
The ClinicalTrials.gov registry entry for NCT02093663 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MMX Mesalamine/Mesalazine (Low Dose) is the first listed.
NCT02093663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093663 about?
NCT02093663 is a clinical study titled "Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis". To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
What is the current status of trial NCT02093663?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2014-12-12. Estimated completion is 2018-11-28.
What interventions are being tested in trial NCT02093663?
The interventions under investigation include: MMX Mesalamine/Mesalazine (Low Dose) (DRUG), MMX Mesalamine/Mesalazine (High Dose) (DRUG).
Who is sponsoring clinical trial NCT02093663?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.